Gould A, Missailidis S. Targeting the hedgehog pathway: the development of cyclopamine and the development of anti-cancer drugs targeting the hedgehog pathway. Mini Rev Med Chem. 2011;11(3):200–13.
Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol. 2013;25(3):218–23.
Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;386(23):2180–8.
Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272:1668–71.
Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature. 2001;411(6835):349–54.
"Skin Cancer Foundation." Basal Cell Carcinoma (BCC). Skin Cancer Foundation, 2013. Web. 09 June 2013.
Wu TP, Stein JA. Nonmelanoma skin cancer in young women. J Drugs Dermatol. 2013;12:568–72.
Koh D, Wang H, Lee J, Chia KS, Lee HP, Goh CL. Basal cell carcinoma, squamous cell carcinoma and melanoma of the skin: analysis of the Singapore Cancer Registry. Br J Dermatol. 2003;148:1161–6.
Weinstock MA, Fisher DE. Indoor ultraviolet tanning: what the data do and do not show regarding risk of melanoma and keratinocyte malignancies. J Natl Compr Canc Netw. 2010;8(8):867–72.
Nan H, Kraft P, Hunter DJ, Han J. Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer. 2009;125(4):909–17.
Alam M, Goldberg LH, Silapunt S, Gardner ES, Strom SS, Rademaker AW, et al. Delayed treatment and continued growth of nonmelanoma skin cancer. J Am Acad Dermatol. 2011;64(5):839–48.
Chren MM, Linos E, Torres JS, Stuart SE, Parvataeni R, Boscardin WJ. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2013;133:1188–96.
Danial C, Lingala B, Balise R, Oro AE, Reddy S, Colevas A, Chang AL. Markedly improved overall survival in 10 consecutive metastatic basal cell carcinoma patients. Br J Dermatol 2013: 1365–2133.
Soleymani AD, Scheinfeld N, Vasil K, Bechtel MA. Metastatic basal cell carcinoma presenting with unilateral upper extremity edema and lymphatic spread. J Am Acad Dermatol. 2008;59(2 suppl 1):s1–3.
Moser S, Borm J, Mihic-Probst D, Jacobsen C, Kruse Gujer AL. Metastatic basal cell carcinoma: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol 2013
Machlin S, Carper K, Kashihara D. Health Care Expenditures for Non-Melanoma Skin Cancer among Adults, 2005–2008 (Average Annual). Rockville: Agency for Healthcare Research and Quality; 2011.
Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283–87.
Haves AW, Schaffer PR, Carucci JA. The Impact of Inoperable Advanced Basal Cell Carcinoma: the Economic, Physical and Psychological Burden of the Disease. J Drugs Dermatol. 2013;12(10):s151–53.
Shingler SL, Garside J, Samanta K, Lear JT, Keohane S, Lloyd AJ. Utilities for advanced basal cell carcinoma. J Med Econ. 2013;16(6):777–83.
Wysong A, Aasi SZ, Tang JY. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. JAMA Dermatol. 2013;149(5):615–6.
Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH, Scott MP. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science. 1997;276(5313):817–21.
Aszterbaum M, Rothman A, Johnson RL, Fisher M, Xie J, Bonifas JM, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Derm. 1998;110(6):885–8.
Wollina U, Tchernev G. Advanced basal cell carcinoma. Wien Med Wochenschr 2013
Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743–54.
Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90–2.
Skvara H, Kalthoff F, Meingassner JG, Wolff-Winiski B, Aschauer H, Kelleher JF, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011;131(8):1735–44.
Atwood SX, Chang AS, Oro AE. Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol. 2012;199(2):193–7.
Keeler RF, Binns W. Teratogenic compounds of Veratrum Californicum Coparison of Cyclopian effects of steroidal alkaloids. Teratology. 1968;1:5–10.
Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smothened. Gene Dev. 2002;16:2743–48.
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.
Chang AL, Atwood SX, Tartar DM, Oro AE. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. JAMA Dermatol. 2013;149(5):639–41.
Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23(1):23–34.
Jimeno A, Weiss GJ, Miller WH, Gettinger S, Eigl BJ, Chang AL, et al. Phase 1 study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013;19(10):2766–74.
Chang ALS, Soloman JA, Hainsworth JD, Goldberg L, McKenna E, Day B, Chen DM, Weiss GJ. Expanded access study of advanced basal cell carcinoma patients treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2013.
Li ZJ, Mack SC, Mak TH, Angers S, Taylor MD, Hui CC. Evasion of p53 and G2/M checkpoints are characteristic of Hh-driven basal cell carcinoma. Oncogene 2013.
Heller ER, Gor A, Wang D, Hu Q, Lucchese A, Kanduc D, et al. Molecular signatures of basal cell carcinoma susceptibility and pathogenesis: a genomic approach. Int J Oncol. 2013;42(2):583–96.
Almquist LM, Karagas MR, Christensen BC, Welsh MM, Perry AE, Storm CA, et al. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer. Carcinogenesis. 2011;32(3):327–30.
Kuijpers DI, Thissen MR, Berretty PJ, Ideler FH, Nelemans PJ, Neumann MH. Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg. 2007;33(5):579–87.
Smeets NW, Kuijpers DI, Nelemans P, Ostertag JU, Verhaegh ME, Krekels GA, et al. Mohs’ micrographic surgery for treatment of basal cell carcinoma of the face—results of a retrospective study and review of the literature. Br J Dermatol. 2004;151(1):141–7.
Hamilton JR, Parvataneni R, Stuart SE, Chrem MM. Recurrence 5 years after treatment of recurrent cutaneous basal cell and squamous cell carcinoma. JAMA Dermatol. 2013;149(5):616–8.
Avril MF, Auperin A, Margulis A, Gerbaulet A, Duvillard P, Benhamou E, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer. 1997;76(1):100–6.
Hall VL, Leppard BJ, McGill J, Kesseler ME, White JE, Goodwin P. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol. 1986;37(1):33–4.
Amin SH, Tibes R, Kim JE, Hybarger CP. Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma. Laryngoscope. 2010;120(12):2456–9.
Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164–72.
Moeholt K, Aagaard H, Pfeiffer P, Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma a review of the literature. Acta Oncol. 1996;35(6):677–82.
Guthrie TH, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal cell carcinoma and squamous cell carcinoma of the skin: results in 28 aptients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8(2):342–6.
Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999;22(1):32–4.
Carneiro BA, Watkin WG, Mehta UK, Brockstein BE. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest. 2006;24(4):396–400.
Khandekar JD. Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy: a report of two patients. Arch Dermatol. 1990;126(12):1,660.